Safety and Efficacy of Chloroquine Associated With Dehydroepiandrosterone Sulphate to Treat Uncomplicated Falciparum Malaria

• Status: Suspended
• Trial end date: 2002-09-01
• Target enrollment: 0
• Participant gender: All

Summary

This study aims to evaluate the safety and efficacy of a standard chloroquine drug regimen administration supplemented with dehydroepiandrosterone sulfate against drug-resistant malaria.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Université Victor Segalen Bordeaux 2
• Treatments: Chloroquine; Chloroquine diphosphate; Dehydroepiandrosterone

Criteria

Inclusion Criteria:

• signing an informed consent (informed consent was given by legal guardian for children);

• age egal or more than 15 years;

• fever (axillary temperature egal or more than 37.5 °C and less than 40°C) or a history of fever within the last 24 hours;

• no sign suggestive of other febrile illness;

• absence of signs of complicated malaria (WHO criteria);

• willingness to participate in follow-up for 14 days

• a positive thick blood film for P. falciparum without other detectable infectious microorganisms

Exclusion Criteria:

• patients taking glucocorticoids or other immuno-suppressive drugs, or indicating recent antimalarial drug history (verbal questionnaire);

• severe malaria;

• mixed infections;

• women using contraceptives;

• pregnant women;

• breast-feeding women.